Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626000088347) titled 'Phase II Clinical Trial of Drug Combinations Guided by Ex-vivo Testing in Patients With Relapsed/Refractory T-cell Lymphoma (COMBINEX-T)' on Jan. 23.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Efficacy
Primary Sponsor: National University Hospital Singapore
Condition:
Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Intervention:
This study uses the Qua...